You just read:

Novartis Survey Reveals Burden of Myeloproliferative Neoplasms (Rare Blood Cancers) on Patients' Daily Activity and Ability to Work, Calling for More Proactive Symptom Assessment

News provided by

Novartis UK

23 Jun, 2017, 08:40 BST